iPreFlight Genesis™ Pro Significantly Extends APG’s Industry-leading Performance Solutions by Adding Proven and Fully Integrated International Flight Planning and Management Workflow for Dispatchers and Flight Crews
NBAA-BACE – Aircraft Performance Group (APG) announces iPreFlight Genesis™ Pro, a new solution that seamlessly coordinates between aircraft dispatchers and flight crews, enabling optimized global flight planning with integrated enroute, take-off, and landing performance. iPreFlight Genesis Pro is the culmination of APG’s proven track record of 20+ years of providing trusted runway performance for over 350 aircraft profiles and over 9,000 monitored airports combined with RocketRoute’s global routing and filing capabilities and Seattle Avionics’ global ChartData. APG, RocketRoute, and Seattle Avionics all recently joined forces under the AFV Partners LLC umbrella.
iPreFlight Genesis Pro provides optimized and fully integrated tools for both dispatchers and flight crews. Dispatchers have access to a comprehensive and flexible web-based application for global routing, runway performance, weight and balance, and flight plan calculation and filing. Flight crews can use the iPad application to review and modify trip plans at any point during the mission, verify runway performance calculations, and check weight and balance parameters. Routes and flight plans are fully synchronized between the web and iPad applications enabling seamless bi-directional collaboration between pilots and dispatchers, eliminating inefficient phone calls, significantly decreasing operational change reaction times, and improving communication accuracy.
“Flight preparation boils down to one important question: What is the most safe, compliant, efficient, and timely manner to get to my destination based on optimized routing considering my aircraft's performance capabilities?” said Shawn Mechelke, president of the Aviation Group at AFV Partners. “APG’s runway performance system is the industry leader in business aviation. Now, with global route optimization and flight plan filing from RocketRoute and global charts from Seattle Avionics, iPreFlight Genesis Pro brings together the many data, calculations, and performance considerations into a seamless interface that is powerful, easy to use, and integrated in both mobile and web applications – no matter where in the world a mission takes you.”
“iPreFlight Genesis Pro uniquely combines the assets and IP of all three companies within our Aviation Group to optimize the flight route based on multiple parameters such as type of aircraft, load factor, weather conditions, and many more data points to deliver a high return on investment solution with a meaningful sustainability impact due to an optimized fuel burn profile for our customers,” said Tony Aquila, founder, chairman, and CEO of AFV Partners. “This solution is the first of many that will leverage the people, technology, and data across APG, RocketRoute, and Seattle Avionics to create new products that will have a lasting positive impact on aviation and the environment.”
KEY BENEFITS
- Realtime responsiveness delivers a superior experience to clients
- Simplifies dispatcher and crew workflow
- Lowers training costs
- Reduces unplanned downtime
- Lowers operating costs and total cost of ownership
KEY FEATURES
- Bi-directional synchronization between dispatchers and flight crews
- Integrated runway performance with flight planning
- Global routing and filing
- Weight and Balance
- Global charts for in-flight and pre-flight use
- Supports web platforms and mobile devices
- Application Programming Interfaces (APIs) allow connection to customer applications
About Aircraft Performance Group
Aircraft Performance Group (APG) is a leading global provider of proprietary flight operations software solutions into the aftermarket of the aerospace industry. APG operates a SaaS business model focused on the corporate and business aviation segment of the aerospace industry. www.flyapg.com
About RocketRoute
RocketRoute is a leading software platform simplifying route planning and flight plan submissions to air traffic controllers. RocketRoute solutions span private, business and commercial aviation, and are the backbone to many air rescue operations in Europe. www.rocketroute.com
About Seattle Avionics
Seattle Avionics creates compelling pre-flight and in-flight user experiences with its cloud-based solutions providing direct user access to flight planning, weather, fuel prices and group document management for the general aviation market. Their ChartData brand of global FAA-certified and georeferenced charts and data is proven and used in leading in-panel avionics systems around the world. www.seattleavionics.com
About AFV Partners
Founded by serial technology entrepreneur and investor Tony Aquila and anchored by some of the world’s largest and most experienced investors, AFV Partners is a long-term sustainable capital vehicle that invests globally in mission critical software, data and disruptive marketplaces that contribute to a net positive impact on the environment. AFV Partners is headquartered in Argyle, TX with offices in Jackson Hole, WY and Zurich, Switzerland. www.afvpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005683/en/
Contact information
John Rutter
johnr@seattleavionics.com
+1 206 779 2067
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom